NAFLD患者无创检查诊断进展性肝纤维化的准确性:个体患者数据荟萃分析
该个体患者数据荟萃分析纳入37项原始研究(n=5735),评估LSM-VCTE、FIB-4和NFS对NAFLD进展性肝纤维化的诊断准确性。LSM-VCTE的AUROC为0.85,FIB-4为0.76,NFS为0.73。序贯联合FIB-4和LSM-VCTE可减少肝活检需求。
要点
- LSM-VCTE诊断进展性肝纤维化的AUROC为0.85,优于FIB-4和NFS。
- 序贯FIB-4(<1.3;≥2.67)后LSM-VCTE(<8.0;≥10.0 kPa)敏感性66%、特异性86%。
- 序贯FIB-4(<1.3;≥3.48)后LSM(<8.0;≥20.0 kPa)敏感性38%、特异性90%。
核心结论
- 序贯联合低切-off排除进展性肝纤维化、高切-off诊断肝硬化的标志物策略可减少肝活检需求。
研究设计与样本
- 个体患者数据荟萃分析,纳入37项原始研究,共5735例患者,45%为女性,中位年龄54岁,中位BMI 30 kg/m2,33%有2型糖尿病,30%有进展性肝纤维化。
主要发现
- LSM-VCTE、FIB-4和NFS诊断进展性肝纤维化的AUROC分别为0.85、0.76和0.73。
- 序贯FIB-4(<1.3;≥2.67)后LSM-VCTE(<8.0;≥10.0 kPa)排除或诊断进展性肝纤维化的敏感性66%(95%CI 63-68)、特异性86%(95%CI 84-87),33%需肝活检。
- 序贯FIB-4(<1.3;≥3.48)后LSM(<8.0;≥20.0 kPa)排除进展性肝纤维化或诊断肝硬化的敏感性38%(95%CI 37-39)、特异性90%(95%CI 89-91),19%需肝活检。
关键数值与推荐
- LSM-VCTE诊断进展性肝纤维化的AUROC为0.85。
- FIB-4诊断进展性肝纤维化的AUROC为0.76。
- NFS诊断进展性肝纤维化的AUROC为0.73。
- 序贯FIB-4(<1.3;≥2.67)后LSM-VCTE(<8.0;≥10.0 kPa)的敏感性66%(95%CI 63-68)、特异性86%(95%CI 84-87),33%需肝活检。
- 序贯FIB-4(<1.3;≥3.48)后LSM(<8.0;≥20.0 kPa)的敏感性38%(95%CI 37-39)、特异性90%(95%CI 89-91),19%需肝活检。
临床怎么用
- 可采用序贯FIB-4和LSM-VCTE策略,低切-off排除进展性肝纤维化,高切-off诊断肝硬化,减少肝活检。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Liver biopsy is still needed for fibrosis staging in many patients with non-alcoholic fatty liver disease. The aims of this study were to evaluate the individual diagnostic performance of liver stiffness measurement by vibration controlled transient elastography (LSM-VCTE), Fibrosis-4 Index (FIB-4) and NAFLD (non-alcoholic fatty liver disease) Fibrosis Score (NFS) and to derive diagnostic strategies that could reduce the need for liver biopsies. DESIGN: Individual patient data meta-analysis of studies evaluating LSM-VCTE against liver histology was conducted. FIB-4 and NFS were computed where possible. Sensitivity, specificity and area under the receiver operating curve (AUROC) were calculated. Biomarkers were assessed individually and in sequential combinations. RESULTS: Data were included from 37 primary studies (n=5735; 45% women; median age: 54 years; median body mass index: 30 kg/m2; 33% had type 2 diabetes; 30% had advanced fibrosis). AUROCs of individual LSM-VCTE, FIB-4 and NFS for advanced fibrosis were 0.85, 0.76 and 0.73. Sequential combination of FIB-4 cut-offs (<1.3; ≥2.67) followed by LSM-VCTE cut-offs (<8.0; ≥10.0 kPa) to rule-in or rule-out advanced fibrosis had sensitivity and specificity (95% CI) of 66% (63-68) and 86% (84-87) with 33% needing a biopsy to establish a final diagnosis. FIB-4 cut-offs (<1.3; ≥3.48) followed by LSM cut-offs (<8.0; ≥20.0 kPa) to rule out advanced fibrosis or rule in cirrhosis had a sensitivity of 38% (37-39) and specificity of 90% (89-91) with 19% needing biopsy. CONCLUSION: Sequential combinations of markers with a lower cut-off to rule-out advanced fibrosis and a higher cut-off to rule-in cirrhosis can reduce the need for liver biopsies.
引用
- Mózes FE, Lee JA, Selvaraj EA, et al. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. Gut. 2021. PMID: 34001645. doi:10.1136/gutjnl-2021-324243
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。